Clinical predictors of all-cause mortality and heart failure readmissions after intermittent levosimendan

11 May 2026 (08:30 - 10:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Rodrigo Brandao

Hospital Professor Doutor Fernando Fonseca, Amadora (Portugal)

5 More presentations in this session

Presentation thumbnail

Tafamidis non-responders in cardiac amyloidosis: clinical characterization of a real-world cohort

Doctor I. Cruz (Coimbra, PT)

Abstract Slides

Presentation thumbnail

Effect of intravenous repletion of ferric hydroxide sucrose on the functional capacity of pacients with heart failure

Mrs A. Freitas (Curitiba, BR)

Abstract Slides

Presentation thumbnail

One-year maintenance of SGLT2 inhibitor therapy in octogenarians following acute heart failure with preserved or mildly reduced ejection fraction

Mrs S. Valdivielso (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Predicted natriuretic output and cardiorenal phenotyping in hospitalised heart failure

Doctor S. Singh (Hartford, US)

Abstract Slides

Presentation thumbnail

Clinical profile, treatment selection, and early outcomes with TTR stabilizers to treat patients with transthyretin cardiac amyloidosis: a real-world study

Doctor R. Esculudes Dos Santos Ferrao Gomes (Lisboa, PT)

Abstract Slides

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy (4)

The Event

Event poster

Heart Failure 2026

11 May 2026 08:30 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Webinar

MRAs in heart failure: what's old is new again

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources